Vaxxas, has announced the company has been granted a licence to develop a next-generation vaccine antigen (DS2).

This review seeks to familiarize the readers with RSV rapid antigen-detection tests, describe their performance characteristics and comment on their strengths and weaknesses. The authors will ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

Pediatric RSV off-season outbreaks and positivity rates increased in China during the COVID-19 pandemic, according to study findings.

The second group of viral antigen-based techniques consists of commercially available immunoassays, commonly referred to as RADTs. Compared with IF, the principle of RSV RADTs is similar in that a ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...

And we believe Matrix-M has the potential to be antigen-sparing and reduce cost of production ... First, we intend to move ...

But what kind of sickness do your symptoms point to? Here's a breakdown for COVID-19, flu and more — and why testing is so ...

Earlier this month, the Food and Drug Administration authorized the Healgen Scientific's Rapid Check COVID-19/Flu A&B Antigen Test for ... breathing at all." RSV, or respiratory syncytial virus ...

Licensed to Vaxxas for worldwide use, this next-generation vaccine antigen (DS2) was developed and optimized by NIH’s scientists to prompt a more robust and durable immune response against RSV ...

Learn about the extended expiration dates of Covid tests and how to order free tests. Stay informed about the latest updates ...